drugset / Trial / NCT03946800
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate MEDI1191 administered intratumorally in sequential and concurrent combination with intravenous durvalumab in patients with solid tumors.
Timeline
- Start
- 2019-05-08
- Primary completion
- 2023-08-24
- Completion
- 2023-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI1191 | Unknown | — | Other |
| Background | Durvalumab | Monoclonal antibody | — | Intravenous |